EDNRA and focal segmental glomerulosclerosis: The phase 2 DUET trial investigating the efficacy and safety of sparsentan, a dual ETAR and angiotensin receptor blocker, showed that sparsentan was more effective in reducing proteinuria than a single angiotensin receptor blocker in patients with FSGS.47